Back to all announcements

DJ Hardman & Co Research: Incanthera (INC): Preparing Sol for commercialisation

 
 Hardman & Co Research 
Hardman & Co Research: Incanthera (INC): Preparing Sol for commercialisation 
 
19-Jun-2020 / 07:30 GMT/BST 
 
       Hardman & Co Research: Preparing Sol for commercialisation 
 
Incanthera (INC) is a spin-out from the Institute of Cancer Therapeutics (ICT) 
  at the University of Bradford to exploit development opportunities generated 
by ICT. This has provided the company with its core pro-drug delivery platform 
 technology, to which additional technologies/products have been acquired, all 
 focused on producing better clinical outcomes for cancer patients. INC listed 
     on the Aquis Exchange in February 2020, raising GBP1.2m new capital for the 
development of an advanced topical skin product, Sol, that prevents sun damage 
developing into skin cancers, which should be ready for commercialisation with 
              a partner in the near term. 
 
              Please click on the link below for the full report: 
 
https://www.hardmanandco.com/research/corporate-research/preparing-sol-for-com 
mercialisation/ [1] 
 
If you are interested in meeting the company, you can register your interest 
by clicking on the above link 
 
To contact us:              Contact: 
 
Hardman & Co                Martin Hall      mh@hardmanandco.com 
35 New Broad Street 
London                      +44 20 7194 7622 
EC2M 1NH 
 
www.hardmanandco.com 
 
Follow us on Twitter 
@HardmanandCo 
 
 Hardman & Co Research can still be accessed for free after MiFID II. Please 
       click here [2] to read the statement. 
 
          About Hardman & Co: For the past 25 years Hardman has been producing 
specialist research designed to improve investors' understanding of companies, 
        sectors, industries and investment securities. Our analysts are highly 
experienced in their sectors, and have often been highly rated by professional 
      investors for their knowledge. Our focus is to raise companies' profiles 
       across the UK and abroad with outstanding research, investor engagement 
 programmes and advisory services. Some of our notes have been commissioned by 
   the company which is the subject of the note; this is clearly stated in the 
              disclaimer where this is the case. 
 
 Hardman Research Ltd, trading as Hardman & Co, is an appointed representative 
        of Capital Markets Strategy Ltd and is authorised and regulated by the 
   Financial Conduct Authority; our FCA registration number is 600843. Hardman 
            Research Ltd is registered at Companies House with number 8256259. 
 
Our research is provided for the use of the professional investment community, 
       market counterparties and sophisticated and high net worth investors as 
  defined in the rules of the regulatory bodies. It is not intended to be made 
  available to unsophisticated retail investors. Anyone who is unsure of their 
   categorisation should consult their professional advisors. This research is 
neither an offer, nor a solicitation, to buy or sell any security. Please read 
              the note for the full disclaimer. 
 
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
End of Announcement - EQS News Service 
 
1073953 19-Jun-2020 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=38b4623e4c23ef014e6ffb0a347eb5ff&application_id=1073953&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=1073953&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

June 19, 2020 02:30 ET (06:30 GMT)